(VIR) Vir Biotechnology - Ratings and Ratios
Antibodies, Vaccines, T-Cell Engagers, Oncology, Infectious Diseases
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 68.3% |
| Value at Risk 5%th | 96.4% |
| Relative Tail Risk | -14.21% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.07 |
| Alpha | -45.60 |
| CAGR/Max DD | -0.46 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.536 |
| Beta | 1.506 |
| Beta Downside | 1.252 |
| Drawdowns 3y | |
|---|---|
| Max DD | 86.13% |
| Mean DD | 63.69% |
| Median DD | 70.52% |
Description: VIR Vir Biotechnology December 24, 2025
Vir Biotechnology (NASDAQ:VIR) is a clinical-stage biopharma focused on discovering and developing therapeutics for serious infectious diseases, with a parallel effort targeting solid-tumor oncology indications.
The company’s pipeline includes an investigational therapy for hepatitis delta virus (HDV) and a suite of preclinical candidates against influenza A/B, SARS-CoV-2, RSV, human metapneumovirus, and HPV. Recent data from its HDV program showed a 70% reduction in viral load in a Phase 2 cohort, positioning it as a potential first-in-class treatment.
Vir leverages a network of strategic alliances: a grant from the Gates Foundation, a licensing deal with Brii Biosciences, a collaboration with Alnylam on RNA-targeted therapeutics, and a multi-product partnership with Sanofi that grants exclusive rights to its protease-cleavable masking platform for both oncology and infectious-disease T-cell engagers.
Financially, Vir reported $115 million in cash and marketable securities at the end of Q3 2024, giving it runway through 2026 without dilutive financing. The biotech sector’s growth is being driven by heightened investor appetite for pandemic-preparedness platforms and a 12% YoY increase in R&D spending across the industry, which supports Vir’s multi-pathogen strategy.
For a deeper dive into VIR’s valuation metrics and scenario analysis, consider exploring ValueRay’s analyst toolkit.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-499.7m TTM) > 0 and > 6% of Revenue (6% = 1.01m TTM) |
| FCFTA -0.45 (>2.0%) and ΔFCFTA -13.59pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 2790 % (prev 1183 %; Δ 1607 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.44 (>3.0%) and CFO -453.5m > Net Income -499.7m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 7.25 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (138.9m) change vs 12m ago 1.67% (target <= -2.0% for YES) |
| Gross Margin -2601 % (prev -542.7%; Δ -2058 pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 1.34% (prev 5.25%; Δ -3.91pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -21.96 (EBITDA TTM -511.5m / Interest Expense TTM -23.8m) >= 6 (WARN >= 3) |
Altman Z'' -8.90
| (A) 0.46 = (Total Current Assets 545.7m - Total Current Liabilities 75.2m) / Total Assets 1.02b |
| (B) -1.13 = Retained Earnings (Balance) -1.15b / Total Assets 1.02b |
| warn (B) unusual magnitude: -1.13 — check mapping/units |
| (C) -0.42 = EBIT TTM -523.2m / Avg Total Assets 1.26b |
| (D) -5.18 = Book Value of Equity -1.16b / Total Liabilities 223.4m |
| Total Rating: -8.90 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 29.57
| 1. Piotroski 0.0pt |
| 2. FCF Yield data missing |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.13 |
| 5. Debt/Ebitda 0.14 |
| 6. ROIC - WACC (= -63.55)% |
| 7. RoE -50.75% |
| 8. Rev. Trend -42.38% |
| 9. EPS Trend -44.49% |
What is the price of VIR shares?
Over the past week, the price has changed by +2.05%, over one month by -9.42%, over three months by +6.62% and over the past year by -25.03%.
Is VIR a buy, sell or hold?
- Strong Buy: 2
- Buy: 5
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the VIR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 17.2 | 188.9% |
| Analysts Target Price | 17.2 | 188.9% |
| ValueRay Target Price | 4.1 | -31.7% |
VIR Fundamental Data Overview January 06, 2026
P/E Forward = 4.3611
P/S = 49.0156
P/B = 1.0381
Beta = 1.345
Revenue TTM = 16.9m USD
EBIT TTM = -523.2m USD
EBITDA TTM = -511.5m USD
Long Term Debt = 100.2m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 8.96m USD (from shortTermDebt, last quarter)
Debt = 100.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -69.9m USD (from netDebt column, last quarter)
Enterprise Value = 420.1m USD (826.4m + Debt 100.2m - CCE 506.5m)
Interest Coverage Ratio = -21.96 (Ebit TTM -523.2m / Interest Expense TTM -23.8m)
FCF Yield = -109.6% (FCF TTM -460.4m / Enterprise Value 420.1m)
FCF Margin = -2731 % (FCF TTM -460.4m / Revenue TTM 16.9m)
Net Margin = -2964 % (Net Income TTM -499.7m / Revenue TTM 16.9m)
Gross Margin = -2601 % ((Revenue TTM 16.9m - Cost of Revenue TTM 455.4m) / Revenue TTM)
Gross Margin QoQ = -9999 % (prev -7933 %)
Tobins Q-Ratio = 0.41 (Enterprise Value 420.1m / Total Assets 1.02b)
Interest Expense / Debt = 0.24% (Interest Expense 239.0k / Debt 100.2m)
Taxrate = -0.10% (negative due to tax credits) (168.0k / -163.0m)
NOPAT = -523.7m (EBIT -523.2m * (1 - -0.10%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 7.25 (Total Current Assets 545.7m / Total Current Liabilities 75.2m)
Debt / Equity = 0.13 (Debt 100.2m / totalStockholderEquity, last quarter 796.1m)
Debt / EBITDA = 0.14 (negative EBITDA) (Net Debt -69.9m / EBITDA -511.5m)
Debt / FCF = 0.15 (negative FCF - burning cash) (Net Debt -69.9m / FCF TTM -460.4m)
Total Stockholder Equity = 984.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -49.01% (Net Income -499.7m / Total Assets 1.02b)
RoE = -50.75% (Net Income TTM -499.7m / Total Stockholder Equity 984.4m)
RoCE = -48.24% (EBIT -523.2m / Capital Employed (Equity 984.4m + L.T.Debt 100.2m))
RoIC = -53.20% (negative operating profit) (NOPAT -523.7m / Invested Capital 984.4m)
WACC = 10.34% (E(826.4m)/V(926.6m) * Re(11.57%) + D(100.2m)/V(926.6m) * Rd(0.24%) * (1-Tc(-0.00)))
Discount Rate = 11.57% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.59%
Fair Price DCF = unknown (Cash Flow -460.4m)
EPS Correlation: -44.49 | EPS CAGR: -27.42% | SUE: 2.26 | # QB: 1
Revenue Correlation: -42.38 | Revenue CAGR: -88.55% | SUE: -0.08 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.60 | Chg30d=+0.037 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=-2.88 | Chg30d=+0.036 | Revisions Net=+0 | Growth EPS=+12.7% | Growth Revenue=-58.5%
Additional Sources for VIR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle